• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans
  • .org
  • Districts
  • Media
  • SupportUs
  • Collaborate
  • Contact
  • Search
  • Join


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

Started by caliban , Mar 25 2011 01:11 AM
economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#301 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 19 August 2013 - 01:10 PM

BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult ...
EON: Enhanced Online News (press release) - Aug 19, 2013
BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC ...

View the full article

#302 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 August 2013 - 03:15 PM

BioTime Receives Approval to Begin Human Clinical Trials of Renevia
DailyFinance - Aug 28, 2013
(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Reneviaâ„¢, a unique biomaterial used as a delivery ...

View the full article

#303 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 31 August 2013 - 04:37 AM

BioTime Appoints Lesley Stolz as EVP of Corporate Development
HispanicBusiness.com - 3 hours ago
BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, has announced the expansion of its senior management team with the appointment of Lesley Stolz , Ph.

View the full article

sponsored ad

  • Advert

#304 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 11 September 2013 - 05:23 AM

BioTime Secures Approval to Begin Human Clinical Trials of Renevia
HispanicBusiness.com - 8 hours ago
BioTime, Inc. announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia, a biomaterial used as a delivery matrix for autologous adipose derived cells to treat the ...

View the full article

#305 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 19 September 2013 - 05:08 PM

BIOTIME, INC. : BioTime Signs Exclusive Agreement with Jade Therapeutics for ...
4-traders (press release) - 20 minutes ago
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with Jade Therapeutics, Inc., a Salt Lake City-based ...

View the full article

#306 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 19 September 2013 - 06:09 PM

BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic ...
DailyFinance - 13 hours ago
(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with Jade Therapeutics, Inc., a Salt ...

View the full article

#307 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 20 September 2013 - 08:46 PM

BioTime (NYSE MKT: BTX) Supersedes, sublicense and supply agreement ...
Proactive Investors USA & Canada - 11 hours ago
BTX signed exclusive sublicense agreement with Jade Therapeutics, Inc., a Salt Lake City-based developer of ophthalmic sustained-release drug delivery platforms.

View the full article

#308 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 30 August 2013 - 05:42 AM

BioTime gets AEMPS approval to begin human clinical trials of Renevia
pharmabiz.com - Aug 30, 2013
BioTime, Inc. has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia, a unique biomaterial used as a delivery matrix for autologous adipose derived cells to treat the loss of ...

View the full article

#309 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 04 October 2013 - 01:05 PM

BioTime Announces Additional Products in Development Based on HyStem(R ...
Wall Street Journal - 8 hours ago
BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform.

View the full article

#310 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 09 October 2013 - 01:11 AM

StemCells gets FDA OK on spinal cord trial
San Francisco Chronicle - 1 hour ago
StemCells Inc. has been testing its neural stem cells in human subjects in Switzerland. So far, seven ... Another Menlo Park company called BioTime announced that it had purchased Geron's stem cell work and may resume its spinal cord trials. And three ...

View the full article

#311 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 15 October 2013 - 01:09 PM

BIOTIME, INC. : BioTime's Subsidiary OncoCyte Corporation and The Wistar ...
4-traders (press release) - 4 hours ago
BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer ...

View the full article

#312 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 10 October 2013 - 12:37 PM

Investors Alert: Geron Corporation (NASDAQ:GERN), Inovio Pharmaceuticals Inc ...
SBWire (press release) - Oct 10, 2013
On January 4, 2013, Geron entered into an Asset Contribution Agreement (the "Agreement") with BioTime, Inc. (NYSE: BTX) and Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation). The closing of the transaction was subject ...

View the full article

#313 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 10 October 2013 - 12:37 PM

Investors Alert: Geron Corporation (NASDAQ:GERN), Inovio Pharmaceuticals Inc ...
SBWire (press release) - Oct 10, 2013
On January 4, 2013, Geron entered into an Asset Contribution Agreement (the "Agreement") with BioTime, Inc. (NYSE: BTX) and Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation). The closing of the transaction was subject ...

View the full article

#314 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 15 October 2013 - 04:38 PM

BIOTIME, INC. : BioTime's Subsidiary OncoCyte Corporation and The Wistar ...
4-traders (press release) - Oct 15, 2013
(BUSINESS WIRE)--Oct. 15, 2013-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to ...

View the full article

#315 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 21 October 2013 - 12:07 PM

MANNKIND CORPORATION : Divestiture, Clinical Study Updates, New Drug ...
4-traders (press release) - 2 hours ago
On October 1, 2013, Geron Corporation (Geron) reported the completion of the transaction for the divestiture of its stem cell assets, following an Asset Contribution Agreement it had entered with BioTime, Inc. (BioTime) and Asterias Biotherapeutics, Inc.

View the full article

#316 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 17 October 2013 - 01:14 PM

Geron (Nasdaq: GERN) Shares Skyrocket, Coverage Initiated with a Buy
Benzinga - Oct 17, 2013
On January 4, 2013, GERN entered into an Asset Contribution Agreement with BioTime, Inc. and Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation).

View the full article

#317 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 21 October 2013 - 12:09 PM

Divestiture, Clinical Study Updates, New Drug Application, and Quarterly ...
Wall Street Journal - Oct 21, 2013
On October 1, 2013, Geron Corporation (Geron) reported the completion of the transaction for the divestiture of its stem cell assets, following an Asset Contribution Agreement it had entered with BioTime, Inc. (BioTime) and Asterias Biotherapeutics, Inc.

View the full article

#318 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 21 October 2013 - 12:03 PM

Divestiture, Clinical Study Updates, New Drug Application, and Quarterly ...
PR Newswire (press release) - Oct 21, 2013
On October 1, 2013, Geron Corporation (Geron) reported the completion of the transaction for the divestiture of its stem cell assets, following an Asset Contribution Agreement it had entered with BioTime, Inc. (BioTime) and Asterias Biotherapeutics, Inc.

View the full article

#319 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 12:47 PM

BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013
Business Wire (press release) - 1 minute ago
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City.

View the full article

#320 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 02:15 PM

BIOTIME, INC. : Asterias Biotherapeutics, Inc. Plans to File Registration ...
4-traders (press release) - 2 hours ago
Asterias Biotherapeutics, Inc., a majority-owned subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it plans to file a registration statement with the Securities and Exchange Commission in November 2013 for an underwritten public ...

View the full article

#321 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:49 PM

Hot Activist Stocks, Advanced Micro Devices, Inc. (NYSE:AMD) Radeon R9 290X ...
eMarketsDaily - 2 hours ago
While BioTime, Inc. (NYSEMKT:BTX) released that the completion of enrollment in a safety trial assess ing Renevia, an injectable matrix designed to facilitate the steady engraftment of transplanted cells.

View the full article

#322 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:00 PM

BIOTIME, INC. : BioTime Organizes New ESI BIO Division to Develop ...
4-traders (press release) - 3 hours ago
BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business.
BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013 - Wall Street Journal
BioTime Reports Interim Results on Reneviaâ„¢ Clinical Safety Trial - HispanicBusiness.com

View the full article

#323 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:15 PM

BIOTIME, INC. : BioTime Reports Interim Results on Renevia? Clinical Safety Trial
4-traders (press release) - 6 hours ago
BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of Renevia TM at an investor meeting in New York City.

View the full article

#324 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:10 PM

BIOTIME, INC. : BioTime Reports Interim Results on Reneviaâ„¢ Clinical Safety Trial
4-traders (press release) - 6 hours ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.

View the full article

#325 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:06 PM

BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
Wall Street Journal - 10 hours ago
BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of Renevia™ at an investor meeting in New York City.

View the full article

#326 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 12:48 PM

BIOTIME, INC. : to Provide Company Updates During Investor Day, October 28 ...
4-traders (press release) - 10 hours ago
BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City.

View the full article

#327 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:16 PM

BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market ...
HispanicBusiness.com - 13 hours ago
ESI BIO also plans to develop additional new PureStemâ„¢ human embryonic progenitors and HyStem® products, and will work with BioTime's LifeMap Sciences, Inc. subsidiary to develop and market a new database product. LifeMap Sciences will continue to ...

View the full article

#328 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:00 PM

BIOTIME, INC. : BioTime Organizes New ESI BIO Division to Develop ...
4-traders (press release) - 13 hours ago
BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business.

View the full article

#329 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 29 October 2013 - 06:50 AM

INCY's Got More Proof, AKRX Hits New High, ILMN Opens Wallet, RGLS On Watch
RTT News - 2 hours ago
Asterias Biotherapeutics Inc., a majority-owned subsidiary of BioTime Inc. (BTX: Quote), plans to file a registration statement with the SEC next month for an underwritten public offering of units, with each unit consisting of one share of Series B ...

View the full article

#330 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 28 October 2013 - 01:43 PM

BioTime Reports Interim Results From Renevia Safety Trial - Quick Facts
RTT News - 20 hours ago
BioTime Inc. (BTX: Quote) reported the completion of enrollment in a safety trial evaluating Renevia, an injectable matrix designed to facilitate the stable engraftment of transplanted cells.

View the full article
Back to Ventures & Markets



Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users

  1. LONGECITY
  2. → Round Table Discussion
  3. → Business
  4. → Ventures & Markets
  5. site rules